Zerodha (Trading Account)
FREE Equity Delivery and MF
Flat ₹20/trade Intra-day/F&O
Zerodha (Trading Account)
FREE Equity Delivery and MF
Flat ₹20/trade Intra-day/F&O
|
|
Review By Dilip Davda on August 1, 2017
Vaishali Pharma Ltd (VPL) is a pharma company dealing in pharmaceutical formulations, APIs, surgical products, veterinary supplements catering to domestic and export markets. On domestic front it has major trading in APIs while in export markets it does trading and marketing of APIs, formulations, surgical products etc. VPL has applied for 186 registrations in 13 countries for some of its products out of which it has already received approvals for 71 products from 7 countries and expecting remaining approvals in near term. The company has ISO 9001:2015 certification and is Government recognized “One Star export House”.
To part finance its working capital and general corpus fund needs, the company is coming out with a maiden issue of 1976000 equity share of Rs. 10 each via book building route with a price band of Rs. 71 – Rs. 72 to mobile Rs. 14.03 to Rs. 14.23 crore based on lower and upper price bands. Issue opens for subscription on 07.08.17 and will close on 10.08.17. Minimum application is to be made for 1600 shares and in multiples thereon, thereafter. Post issue, shares will be listed on NSE SME Emerge. Issue is solely lead managed by Pantomath Capital Advisors Pvt Ltd and Bigshare Services Pvt Ltd is the registrar to the issue. VPL has issued most of its equity at par and 1615385 shares for a consideration of Rs. 13 per share in May 2017. It has also issued bonus shares in the ratio of 9 for 1 in March 2010 and 5 for 1 in March 2017. Post issue, its paid up equity capital will stand enhanced from Rs. 4.62 cr. to Rs. 6.59 crore.
On performance front, the company has reported turnover/net profits of Rs. 119.10 cr. / Rs. 0.60 cr. (FY13), Rs. 121.57 cr. / Rs. 0.30 cr. (FY14), Rs. 98.82 cr. / Rs. 0.16 cr. (FY15), Rs. 69.89 cr. / Rs. –(0.03) cr. (FY16) and Rs. 67.11 cr. / Rs. 0.66 cr. (FY17). It has posted declining top line for last five fiscals. It suffered setbacks in bottom lines as well with losses in FY16 and despite lower top line, sudden jump in bottom line for FY17 is a big surprise. Last three fiscal’s average EPS is Rs. 1.16 and Rs. 2.21 for FY 17 on a paid up equity capital of Rs. 3 crore. If we attribute latest earnings on fully diluted equity post issue, then asking price is at a P/E of 72 and at a P/BV of 5.5 making it a costly bet with greedy pricing. Last three fiscal’s average RoNW is 9.10%. As per RHP the company has no listed peer to compare with.
On merchant banker’s front, this is the 41st mandate from its stable, out of last 10 listings, one opened at par with offer price and nine gave positive opening on the listing day.
Conclusion: Exorbitantly priced issue with declining top lines is a high risk bet, hence no harm in giving it a miss.
Review By Dilip Davda on August 1, 2017
DISCLAIMER: No financial information whatsoever published anywhere here should be construed as an offer to buy or sell securities, or as advice to do so in any way whatsoever. All matter published here is purely for educational and information purposes only and under no circumstances should be used for making investment decisions. My reviews do not cover GMP market and operators game plans. Readers must consult a qualified financial advisor before making any actual investment decisions, based the on information published here. With entry barriers, SEBI wants only well-informed investors to participate in such offers. With crazy listings in the recent past, SME IPOs drew the attention of investors across the board and lead to seer madness. However, as SME issues have entry barriers and continued low preference from the broking community, any reader taking decisions based on any information published here does so entirely at their own risk. The above information is based on information available as of date coupled with market perceptions. The Author has no plans to invest in this offer.
About Dilip Davda
Dilip Davda is veteran journalist associated with stock market since 1978. He is contributing to print and electronic media on stock markets/insurance/finance since 1985.
Dilip Davda is a leading reviewer of public issues and NCDs in the primary stock market in India. The knowledge he gained over 3 decades while working in the stock market and a strong relationship with popular lead managers makes his reviews unique. His detail fundamental and financial analysis of companies coming up with IPO helps investors in the primary stock market. Dilip Davda has a special interest in analyzing the SME companies and writing reviews about their public issues. His reviews are regularly published online and in news papers.
(Dilip Davda -SEBI registered Research Analyst-Mumbai,
Registration no. INH000003127 (Perpetual)
Email id: dilip_davda@rediffmail.com ).
The initial public offer (IPO) of Vaishali Pharma Ltd offers an early investment opportunity in Vaishali Pharma Ltd. A stock market investor can buy Vaishali Pharma IPO shares by applying in IPO before Vaishali Pharma Ltd shares get listed at the stock exchanges. An investor could invest in Vaishali Pharma IPO for short term listing gain or a long term.
Read the Vaishali Pharma IPO recommendations by the leading analyst and leading stock brokers.
Vaishali Pharma IPO offers an opportunity to buy IPO shares before they get listed at the stock exchanges. Read the Vaishali Pharma IPO Notes, Analysis and Recommendations by leading stock brokerage firms and experts in the above answer.
Our recommendation for Vaishali Pharma IPO is to avoid.
As per the analysis by our lead analyst Mr. Dilip Davda, we suggest you to avoid the Vaishali Pharma IPO.
The Vaishali Pharma IPO allotment status will be available on or around [.]. The allotted shares will be credited in demat account by [.]. Visit Vaishali Pharma IPO allotment status to check.
FREE Intraday Trading (Eq, F&O)
Flat ₹20 Per Trade in F&O
|
|
RHP
